MLTX Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own MLTX shares is 177, representing 98.15% of the company's common stock.

JEFFERIES FINANCIAL GROUP INC., in the last quarter, reduced its stake in MLTX by -49.43% restricting it's holding to 8.8 thousand shares of worth nearly $442.02K. ENVESTNET ASSET MANAGEMENT INC also lessened -7.4% of the MLTX shares from its portfolio, reducing its holding to 8.44 thousand shares of worth $424.04K. LPL FINANCIAL LLC also shunned MLTX shares holding by -8.53% last quarter which brought its holding to 6.65 thousand shares worth $333.83K.

As per its latest 13F filing, QUBE RESEARCH & TECHNOLOGIES LTD increased its stake in MLTX by 100% in the last quarter. The institutional holder raised its holding to 11.3 thousand shares having worth more than $567.60K. TREXQUANT INVESTMENT LP also added 100% more shares of MLTX to its portfolio, raising its holding to 9.7 thousand shares of worth $487.08K. NEW YORK STATE COMMON RETIREMENT FUND also increased its MLTX shares holding by 8,983.52% which brought its holding to 8.27 thousand shares worth $415.00K.

The insider with the most stakes in MLTX is Chen Bihua , 10 percent owner at the company. Additionally, MLTX stock is highly held by Chief Executive Officer Santos da Silva Jorge and BVF PARTNERS L P/IL among others.

Company executives, directors, and other insiders own 15.22% percent of MoonLake Immunotherapeutics's stock. Within the last six months, there have been 2 transaction(s) in which MLTX insiders have sold stock, totaling 303.55K shares. Insiders that have sold shares include STURGE SIMON, BVF PARTNERS L P/IL, and SANTOS DA SILVA JORGE.

There have been 0 transaction(s) during the past 6-months in which MoonLake Immunotherapeutics insiders have bought stock, totalling 0 shares

Around 1.46M MoonLake Immunotherapeutics shares are held by insiders, which represents about 15.22% of MLTX stock.

MLTX 10 percent owner, Chen Bihua holds the largest portfolio of the company's shares. MLTX shares owned by Chen total nearly 8.49 million.

AVORO CAPITAL ADVISORS LLC is the largest institutional owner in MLTX which holds 2.58 million shares worth $129.59M or 5.25% of the total MLTX shares outstanding followed by JEFFERIES FINANCIAL GROUP INC. with ownership of 8.8 thousand shares representing 0.02% of the MLTX ownership. ALLIANZ ASSET MANAGEMENT GMBH is the third largest stakeholder with 12.3 thousand shares or 0.03% of the ownership worth more than $617.83K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the MLTX is concerned, it is a stock which is optionable.

Number of MLTX shares short is 8.08M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 63.06M shares of MLTX are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, MLTX has 25.99M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for MLTX is 41.54.